Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene-related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine[1].
[1]. Goadsby PJ, Reuter U, HallstrÖm Y, et al. A Controlled Trial of Erenumab for Episodic Migraine.N Engl J Med. 2017;377(22):2123-2132.
















